Medical Marijuana, Inc. Subsidiary HempMeds® Collaborates With Leading Research Hospital in Argentina to Study the Efficiency of CBD for Adult Epilepsy
SAN DIEGO, CA, July 06, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Medical Marijuana, Inc. ( OTC: MJNA ) (the “Company”) , the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands, and supply chain, announced today that its subsidiary HempMeds® is collaborating with Hospital del Cruce to conduct the first study in Argentina on the efficiency of CBD as a treatment for epilepsy in adults. The company will be donating its hemp-derived RSHO-X 5,000mg CBD products for the study. The Ministry of Health of Argentina has authorized Hospital del Cruce, the leading research venue in Argentina, to import HempMeds® products and execute the study. The study, led by Dr. Silvia Kochen, a renowned neurologist who works as the Executive Director of Neuroscience Studies and Complex Systems at the Epilepsy Center of Hospital del Cruce, will become part of ...